Catalyst overview
Research summary
This catalyst tracks a Failed discontinued for MBX 1416 in Post-Bariatric Hypoglycemia. The expected timing is based on the latest available company guidance and may change.
1/7/25- Presented positive Ph1 topline data. 6/23/25- Presented Safety, PK, and PD data at ADA'25. 2025. Ph2 trial initiation in H2 2025. 11/06/25:- First patient dosed in Ph2a STEADI trial; STEADI results expected Q2 2026. 03/12/26:- Ongoing Ph2a STEADI trial of once-weekly imapextide; results remain expected in Q2 2026. 05/07/26:- STEADI Ph2a PBH trial results reiterated for Q2 2026. 05/11/26:- STEADI Ph2a showed proof of concept; company will not fund Ph2b in PBH.
Verification
Confirm timing and program details against the company announcement or filing.